Publications

Manuscripts

  • Grossman SA, Ye X, Chamberlain M, Mikkelsen T, Batchelor TT, Desideri S, Piantadosi S, Fisher JD, Fine HA: Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: A multicenter phase II trial for the NABTT CNS Consortium. JCO (in press 2009)
  • Wu W, Lamborn KR, Buckner JC, Novotny PJ, Chang SM, O’Fallon JR, Jaeckel KA, Prados MD: Joint NCCTG and NABTC prognostic factors analysis for high grade recurrent glioma. Neuro-Oncology (in press 2009)
  • Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WKA, Gilbert MR, Aldape KA, Wen P, Fine HA, Mehta M, DeAngelis LM, Lieberman F, Cloughesy TF, Robins IH, Dancey J, Prados MD: A phase I trial of erlotinib in patients with non-progressive glioblastoma multiforme post radiation therapy, and recurrent malignant gliomas and meningiomas: A North American Brain Tumor Consortium Trial. Neuro-Oncology (in press 2009)
  • Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Robins IH, Junck L, Salazar AM, Chang SM: A North American Brain Tumor Consortium phase-2 study of poly-ICLC for adult patients with recurrent anaplastic glioma. J Neurooncol 91 (2): 183-189, 2009
  • Butowski N, Chang SM, Junck L, DeAngelis L, Abrey L, Fink K, Cloughesy T, Lamborn K, Salazar A, Prados MD: A North American Brain Tumor Consortium (NABTC 01-05) study of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma. J Neurooncol 91(2): 175-182, 2009
  • Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WKA, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, DeAngelis LM, Lieberman F, Cloughesy TF, Robins IH, Dancey J, Prados MD: A phase II trial of erlotinib in patients with recurrent malignant gliomas and non-progressive glioblastoma multiforme post radiation therapy: A North American Brain Tumor Consortium trial. Neuro-Oncology (in press)
  • Wen PW, Yung WKA, Lamborn KR, Norden AD, Cloughesy TF, De Angelis LM, Fine HA, Chang SM, Robins IH, Fink K, Abrey LE, Lassman AB, Mehta M, Drappatz J, Kesari S, Di Tomaso ED, Ligon K, Aldape K, Jain R, Capdeville R, Stiles C, Kaplan R, Ergin MJ, Murgo AT, Prados MD: Phase II study of imatinib mesylate (GleevecĀ®) for recurrent meningiomas (North American Brain Tumor Consortium Study 01-08). Neuro-Oncology March 17, 2009 [Epub ahead of print]

Abstracts

  • Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld MR, Fisher J: Current survival statistics for patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the USA for the NABTT CNS Consortium, ASCO 2009
  • Fiveash JB, Chowdhary SA, Peereboom D, Mikkelsen T, Nabors LB, Lesser GJ, Rosenfeld MR, Ye X, Grossman SA: NABTT-0702: A phase II study of R-(-)-gossypol (AT-101) in recurrent glioblastoma multiforme (GBM) for the NABTT CNS Consortium, ASCO 2009
  • Supko, JG, Grossman SA, Peereboom D, Chowdhary SA, Lesser GJ, Nabors LB, Mikkelsen T, Desideri S, Batchelor TT: Feasibility and phase I trial of tandutinib in patients with recurrent glioblastoma. For the NABTT CNS Consortium, ASCO 2009
  • Nabors LB, Mikkelsen T, Batchelor T, Lesser G, Rosenfeld M, Ye X, Piantadosi S, Olson J, Brem S, Grossman S: NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) for the NABTT CNS Consortium, ASCO 2009
  • Rosenfeld MR, Chamberlain M, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X: A phase II study of chemoradiation followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma: 12 and 18 month survival data (NABTT 0501). For the NABTT CNS Consortium, ASCO 2009
  • Grossman SA, Ye X, Peereboom D, Rosenfeld MR, Mikkelsen T, Desideri S: Phase I Study of Teremeprecol in Patients with Recurrent High Grade Glioma for the NABTT CNS Consortium, WFNO-Asian Society 2009
  • Grossman SA, Ye X, Chamberlain M, Mikkelsen T, Batchelor T, Desideri S, S Piantadosi, Fine H: Survival results from a multicenter phase II trial of Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma. WFNO-Asian Society 2009
  • Kuhn JG, Gilbert M, Wen P, Cloughesy T, Cooper J, Puduvalli V, DeAngelis L, Lieberman F, Lamborn K, Prados M: Interaction between sorafenib and erlotinib. J Clin Oncol 27: 15s, 2009
  • Chang SM, Kuhn J, Lamborn K, Cloughesy T, Robins I, Lieberman F, Yung A, Dancey J, Prados M, Wen P: Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant glioma (NABTC 04-02). J Clin Oncol 27, 15s, 2009
  • Norden AD, Raizer JJ, Lamborn KR, Abrey LE, Chang SM, Gilbert MR, Cloughesy TF, Prados MD, Lieberman F, Wen P: Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas. J Clin Oncol 27: 15s, 2009
  • Wen PY, Cloughesy T, Kuhn J, Lamborn K, Abrey LE, Lieberman F, Robins HI, Wright J, Prados MD, Gilbert M: Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (NABTC 05-02). J Clin Oncol 27: 15s, 2009
  • Prados M, Gilbert M, Kuhn J, Lamborn K, Cloughesy T, Lieberman F, Puduvalli V, Robins HI, Lassman A, Wen PY: Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (NABTC 05-02).J Clin Oncol 27: 15s, 2009
  • Piao Y, Heymach JV, Bekele B, Camphausen K, Wen PY, Liu J, Yung WK, De Groot J: Circulating cytokine and angiogenic factors as predictive biomarkers of glioblastoma response to aflibercept (VEGF Trap). J Clin Oncol 27: 15s, 2009